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Inhibition of DPP-4 reduces acute 
mortality after myocardial infarction 
with restoration of autophagic response in type 
2 diabetic rats
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Abstract 
Background: Type 2 diabetes mellitus (T2DM) worsens the outcome after myocardial infarction (MI). Here, we 
hypothesized that inhibition of dipeptidyl peptidase-4 (DPP-4) improves survival after MI in T2DM by modifying 
autophagy in the non-infarcted region of the heart.
Methods and results: Under baseline conditions, there was no significant difference between levels of myocardial 
autophagy marker proteins in OLETF, a rat model of T2DM, and in LETO, a non-diabetic control. However, in contrast 
to the response in LETO, LC3-II protein and LC3-positive autophagosomes in the non-infarcted region of the myo-
cardium were not increased after MI in OLETF. The altered autophagic response in OLETF was associated with lack 
of AMPK/ULK-1 activation, attenuated response of Akt/mTOR/S6 signaling and increased Beclin-1–Bcl-2 interaction 
after MI. Treatment with vildagliptin (10 mg/kg/day s.c.), a DPP-4 inhibitor, suppressed Beclin-1–Bcl-2 interaction and 
increased both LC3-II protein level and autophagosomes in the non-infarcted region in OLETF, though it did not 
normalize AMPK/ULK-1 or mTOR/S6 signaling. Plasma insulin level, but not glucose level, was significantly reduced by 
vildagliptin at the dose used in this study. Survival rate at 48 h after MI was significantly lower in OLETF than in LETO 
(32 vs. 82%), despite similar infarct sizes. Vildagliptin improved the survival rate in OLETF to 80%, the benefit of which 
was abrogated by chloroquine, an autophagy inhibitor.
Conclusions: The results indicate that vildagliptin reduces T2DM-induced increase in post-MI acute mortality pos-
sibly by restoring the autophagic response through attenuation of Bcl-2-Beclin-1 interaction.
Keywords: Type 2 diabetes, Autophagy, DPP-4 inhibitor, Myocardial infarction, Mortality
© 2015 Murase et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Diabetes mellitus (DM) is associated with poor outcome 
after acute myocardial infarction (MI) even in the era of 
reperfusion therapy [1, 2]. The poor outcome after MI in 
patients with DM has been explained by extensive ather-
osclerotic lesions, increased myocardial susceptibility to 
ischemia/reperfusion injury, and contractile dysfunction 
of the myocardium, often called “diabetic cardiomyo-
pathy” [3]. Augmentation of contractile function in the 
non-infarcted region is crucial in acute compensation for 
the lost contraction in the infarct region. Thus, pre-exist-
ing contractile dysfunction in patients with DM, if any, 
potentially compromises such a compensatory response 
after MI and increases mortality. Recently, we confirmed 
DM-induced increase in acute mortality after MI in an 
animal model of obese type 2 DM (T2DM), Otsuka-
Long-Evans-Tokushima Fatty rats (OLETF). The mortal-
ity rate at 48 h after MI was significantly higher in OLETF 
due to lethal heart failure than in non-diabetic control 
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rats, Long-Evans-Tokushima-Otsuka rats (LETO), while 
infarct sizes were similar in OLETF and LETO [4]. Inter-
estingly, OLETF had preserved ventricular contractility 
with mildly impaired relaxation under baseline condi-
tions [4]. The findings indicate that the altered response 
of the non-infarcted myocardium, rather than base-
line ventricular contractility, contributes to the T2DM-
induced increase in acute mortality after MI.
Autophagy is a cellular process of lysosome-medi-
ated degradation of cytoplasmic components or dam-
aged organelles in response to cellular stress [5–13]. It 
has been suggested that autophagy has roles in critical 
adaptive mechanisms in the heart under hemodynamic 
stress conditions such as pressure overload [6] and loss 
of a contractile region by MI [5, 7–11]. In the case of MI, 
autophagic activity was augmented in the non-infarcted 
remote area and border area but not in the infarcted 
myocardium after MI, and the autophagic activity pro-
gressively increased in the remote area during a 3-week 
period after MI [8, 9]. The increase in autophagic activity 
has protective effects against remodeling and dysfunc-
tion of the ventricle after MI [8, 9]. However, autophagy 
has been shown to be impaired by DM in non-cardiac 
[14] and cardiac tissues [15–20], though advanced gly-
cogen endproducts reportedly activate autophagy in 
cardiomyocytes [21]. Whether the increase in myocar-
dial autophagic activity after MI is impaired by DM and 
whether such an impairment, if any, is treatable by phar-
macological agents have not been clarified.
We hypothesized that autophagic response of the 
myocardium to MI is impaired by T2DM and that inhi-
bition of dipeptidyl peptidase-4 (DPP-4) would attenu-
ate the T2DM-induced increase in post-MI mortality 
by restoring the autophagic response. The rationale 
for the hypotheses is four-fold. First, a significant asso-
ciation of preserved ventricular function and activa-
tion of autophagy has been demonstrated for different 
types of cardiac stress in non-diabetic animals [5–11]. 
Second, DM impairs intracellular signaling mecha-
nisms relevant to autophagy, including PI3K-Akt sign-
aling, in the myocardium [3]. Third, activation of the 
glucagon-like peptide-1 (GLP-1) receptor or treatment 
with a DDP-4 inhibitor triggers AMP-activated protein 
kinase (AMPK) signaling [22, 23, 24], which facilitates 
autophagy [5, 9, 15, 18, 25]. In fact, a GLP-1 analog, 
liraglutide, has been shown to promote autophagy in 
non-cardiac cells [26]. Fourth, it has been reported 
that the activity of circulating DPP-4 is associated with 
left ventricular dysfunction in patients [27, 28]. Con-
versely, inhibition of DPP-4 and use of a GLP-1 analog 
prevented cardiomyopathy, improved cardiac function 
and post-MI survival rate, and attenuated ventricular 
remodeling in DM and non-DM animals [27, 29–32]. 
To examine the hypotheses, we used OLETF as a model 
of T2DM in the present study as in previous studies 
[4, 33, 34]. Results of the experiments showed that a 
DPP-4 inhibitor, vildagliptin, significantly improved 
survival after MI in OLETF and that the protective 
effect of vildagliptin was closely associated with resto-




The present study was conducted in strict accordance 
with the Guideline for the Care and Use of Labora-
tory Animals published by the US National Institute of 
Health (NIH publication No. 85-23, revised 1996) and 
was approved by the Animal Use Committee of Sap-
poro Medical University. Protocols of the experiments 
are summarized in Fig.  1. Male LETO and OLETF at 
ages of 25–30  weeks were used in all experiments. 
LETO were pretreated with saline, vildagliptin (10  mg/
kg/day), a DPP-4 inhibitor, or exenatide (10 μg/kg/day), 
a GLP-1 receptor agonist, for 2  weeks, or with chloro-
quine (10 mg/kg/day), an autophagy inhibitor [9, 12, 35], 
for 1 week. Vildagliptin was kindly provided by Novartis 
Pharma AG (Basel, Switzerland). The pharmacological 
agents were administered via osmotic minipumps (Alzet, 
Cupertino, CA, USA), not via drinking water contain-
ing the agents, because the amount of water rats drink 
per day is not consistent. The dose of vildagliptin was 
selected on the basis of a result in a previous report [36], 
and we confirmed that this dose of vildagliptin signifi-
cantly increased the serum level of GLP-1 (see “Results”). 
OLETF also received saline, vildagliptin, exenatide or 
chloroquine as did LETO, and an additional group of 
OLETF received both vildagliptin and chloroquine. In 
separate groups of rats, blood samples were collected via 
the carotid artery under anesthesia 12 h after fasting to 
examine the effects of these pharmacological agents on 
metabolic parameters.
Oral glucose tolerance test
An oral glucose tolerance test (OGTT) was performed in 
LETO treated with a vehicle and OLETF treated with a 
vehicle or vildagliptin (10 mg/kg/day) for 2 weeks. After 
fasting for 12  h, rats were administered glucose (2  g/kg 
body weight) by gavage, and blood glucose and insulin 
levels before and after glucose administration were meas-
ured by using a Glutest-mint (Sanwa Kagaku Kenkyusho, 
Nagoya, Japan) and a rat insulin RIA kit (Linco Research 
Inc, St. Charles, MO, USA), respectively. Blood for GLP-1 
assay using a GLP-1 (Active) ELISA kit (Millipore) was 
collected before glucose administration in sampling tubes 
containing a DPP-4 inhibitor.
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Echocardiography
Echocardiography was performed before induction of MI 
as previously reported [4].
Induction of MI and mortality monitoring
Rats were prepared for induction of MI as in our previous 
study [4]. In brief, rats were anesthetized with sodium 
pentobarbital (40  mg/kg, i.p.), and the level of anesthe-
sia was continuously monitored during the experiment 
and an additional dose of pentobarbital was administered 
when necessary. Rats were then intubated and ventilated 
with a rodent respirator (model 683, Harvard Apparatus, 
South Natick, MA, USA). After left thoracotomy, a mar-
ginal branch of the left coronary artery was permanently 
ligated by using a 5–0 silk thread to induce MI. We used 
a permanent occlusion model of MI to avoid the possi-
bility that pharmacological pretreatments modify infarct 
size and induce an inter-group difference in mechanical 
stress on the non-infarcted region. The surgical wounds 
were repaired and the rats were returned to their cages. 
All rats were allowed ad-lib access to water but restricted 
from food for 12 h. Survival rate of rats was determined 
at 24 and 48  h after MI. Rats that had survived at 48  h 
after MI were euthanized by a pentobarbital overdose 
and heart tissue was excised and fixed in 10% formalde-
hyde for infarct size analysis.
Cardiac tissue sampling after MI
Since the mortality rate at 24–48  h after MI was high 
in OLETF at ages of 25–30  weeks [4], myocardial tis-
sue sampling for biochemical analyses and immunohis-
tochemistry was performed at 12  h after MI. Rats were 
anesthetized and ventilated, and blood pressure and 
heart rate were monitored by a catheter placed in the 
carotid artery. The chest was re-opened and the hearts 
were excised and immediately immersed in ice-cold 
saline. The myocardium in the non-infarcted region was 
quickly excised in the saline, frozen in liquid nitrogen, 
and stored at −80°C until use for biochemical and histo-
logical analyses.
Immunohistochemistry
Frozen heart tissues were embedded in OCT compound 
(Tissue-Tek) and snap-frozen in liquid nitrogen. After the 
tissues had been sectioned at 8 μm in thickness with a 
cryostat at −20°C, the sections were incubated with rab-
bit polyclonal anti-LC3 antibody (MBL, PM036, 1:250) in 
PBS containing 1% BSA and 0.3% triton X-100 overnight 
at 4°C. The samples were then incubated with an Alexa 
Fluor 488 anti-rabbit IgG antibody (Invitrogen) for 1  h 
at room temperature. After nuclei had been stained with 
Hoechst33342 (Dojindo, Kumamoto, Japan), samples 
were mounted on slides for image analysis. Fluorescence 
Fig. 1 Experimental protocols. Experimental protocols for survival study (a) and cardiac tissue sampling (b). Vilda vildagliptin, Exe exenatide, CQ 
chloroquine, LV left ventricle.
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images were obtained using a FLoid Cell Imaging Sta-
tion (Life Technologies). The number of LC3 dots was 
counted and analyzed in 40 randomly selected fields from 
five hearts in each group.
Immunoblotting
Frozen tissue samples were homogenized in ice-cold 
buffer (CelLytic™ MT Cell Lysis Reagent) including pro-
tease and phosphatase inhibitor cocktails (Nacalai Tesque, 
Inc., Kyoto, Japan). The homogenate was centrifuged at 
15,000g for 15 min at 4°C to obtain the supernatant. Equal 
amounts of protein were analyzed by immunoblot assays 
using specific antibodies (see Additional file 1: Table S1). 
Intensities of individual bands were quantified by using 
Image J software (National Institutes of Health).
Beclin‑1–Bcl‑2 interaction
Frozen myocardial tissue samples were homogenized in 
ice-cold buffer containing 20 mM Tris (pH 7.4), 137 mM 
NaCl, 10% glycerol, 0.3% CHAPS, and 2 mM EDTA sup-
plemented with protease and phosphatase inhibitor cock-
tails. The homogenates were then centrifuged at 15,000g 
for 15  min to obtain supernatants. After quantification 
of protein concentration, the lysates were incubated for 
30  min with 40  μl of protein A magnetic beads (New 
England Biolads, Ipswich, MA, USA) to remove endog-
enous IgG. Equal amounts (2,000  μg) of lysates were 
incubated with either 6 μg of rabbit anti-Beclin-1 anti-
body or normal rabbit IgG overnight at 4°C. The mixture 
was then incubated with 50 μl of fresh beads for 1 h. The 
beads were washed three times with PBS containing pro-
tease inhibitor cocktail and re-suspended in SDS sample 
loading buffer followed by denaturation. Immunoprecipi-
tated proteins were analyzed by Western blotting initially 
with rabbit anti-Bcl-2 antibody and then with mouse 
monoclonal anti-Beclin-1 antibody after stripping.
mRNA quantification
Total RNA was isolated from myocardial tissues by using 
an RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, 
CA, USA). First-strand cDNA was synthesized using a 
SuperScript VILO™ cDNA Synthesis Kit (Life Technolo-
gies). DNA amplification was performed in StepOne™ 
(Life Technologies). Analyses of B-type natriuretic pep-
tide (BNP) and β-actin mRNA levels were performed by 
using Taqman gene expression assays (Rn00676450_g1 
Nppb and Rn00667869_m1 Actb, respectively). For 
p62 and 18S, we used Power SYBR PCR Master Mix 
(Applied Biosystems, Inc) and the following oligonucle-
otide primers: for rat p62, 5′-ATCAGCCTCTGGTGG 
GAGAT-3′ and 5′-CCCATCCACAGGTGAACTCC-3′; 
for rat 18S, 5′-CGGACAGGATTGACAGATTG-3′ 
and 5′-CAAATCGCTCCACCAACTAA-3′. All assays 
were performed in duplicate and by the standard curve 
method using serial cDNA dilution.
Statistical analyses
Data are presented as mean ± SEM. Differences between 
treatment groups were assessed by one-way analysis of 
variance (ANOVA) followed by the Student–Newman–
Keuls post hoc test for multiple comparisons. Differences 
in time course between two groups in OGTT were ana-
lyzed by 2-way ANOVA for repeated measures followed 
by the Student–Newman–Keuls post hoc test for multi-
ple comparisons. Survival rates after MI were compared 
by Kaplan–Meier curves and log-rank statistics. For all 
tests, p < 0.05 was considered statistically significant.
Results
Metabolic profiles
Data for metabolic profiles of LETO and OLETF and 
the effects of vildagliptin, exenatide and chloroquine on 
metabolic parameters are shown in Table  1. In LETO, 
body weight (531 ± 7 g), fasting blood glucose level and 
serum total cholesterol level were not changed by treat-
ment with vildagliptin or exenatide. OLETF had larger 
body weight (627 ±  14 g) and higher fasting blood glu-
cose level than those of LETO (Table  1), as we previ-
ously reported [4, 34, 37]. Treatment with vildagliptin or 
exenatide at the dose used in the present study did not 
Table 1 Metabolic parameters after treatment
Values are mean ± SEM. N = 4–11.
TC total cholesterol.
* P < 0.05 vs. LETO vehicle; † P < 0.05 vs. OLETF vehicle.
LETO OLETF
Vehicle Vildagliptin Exenatide Vehicle Vildagliptin Exenatide Vildagliptin +  
Chloroquine
Blood glucose (mg/dl) 108 ± 5 106 ± 6 117 ± 12 205 ± 25* 201 ± 13* 251 ± 17* 197 ± 22*
Serum insulin (ng/ml) 2.5 ± 0.5 1.3 ± 0.2 3.1 ± 0.9 5.8. ± 0.9* 2.5 ± 0.5† 1.3 ± 0.8† 4.1 ± 0.9
Serum TC (mg/dl) 82 ± 5 85 ± 5 95 ± 4 117 ± 3 120 ± 6 109 ± 12 96 ± 7
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change body weight and blood glucose level in OLETF. 
Serum insulin level was significantly higher in OLETF 
than in LETO, and both vildagliptin and exenatide 
decreased insulin level in OLETF without reduction in 
blood glucose level (Table 1). Treatment of OLETF with 
chloroquine in addition to vildagliptin affected neither 
insulin level nor blood glucose level compared to the lev-
els in those treated with vildagliptin alone. Despite lack 
of effects on blood glucose level, vildagliptin increased 
serum level of the active form of GLP-1; GLP-1 level was 
below the detection range (<2.0 pmol/L) in 4 of a total of 
five samples from the vehicle-treated OLETF, but it was 
5.0 ± 0.9 pmol/L in vildagliptin-treated OLETF (Fig. 2a).
In OGTTs, levels of blood glucose and serum insu-
lin before and after glucose administration were higher 
in vehicle-treated OLETF than in LETO (Fig.  2b, c). 
Treatment with vildagliptin did not change glucose lev-
els before and after glucose administration in OLETF 
(Fig.  2b). On the other hand, insulin level was signifi-
cantly lower in the vildagliptin-treated OLETF than in 
the vehicle-treated OLETF (Fig. 2c).
Cardiac function was not modified by vildagliptin or 
exenatide at baseline
Before induction of MI, heart rate was lower and left 
ventricular (LV) dimension was larger in OLETF than 
in LETO, though there were no differences in LV ejec-
tion fraction and fractional shortening between the two 
groups (Table 2). Treatment with vildagliptin, exenatide, 
or chloroquine did not alter these echocardiographic 
parameters in either LETO or OLETF. We tried to assess 
LV function at 12 h after coronary ligation also, but clear 
cardiac images for quantitative assessment could not 
be obtained at that time point because of intra-thoracic 
air, fluid and chest wall damage related to open-chest 
surgery.
Vildagliptin improved survival in OLETF in a 
chloroquine‑sensitive manner
The survival rate during a period of 48  h after MI in 
LETO was 82%, which was comparable with the rate in 
our previous study [4]. Pretreatment with vildagliptin or 
exenatide for 2  weeks before MI did not affect the sur-
vival rate in LETO (86 and 80%, respectively) (Fig.  3a). 
As in our previous study [4], the survival rate was sig-
nificantly lower in OLETF (32%, Fig.  3b) than that in 
LETO. Pretreatment of OLETF with vildagliptin signifi-
cantly increased the survival rate (80%) to a level similar 
to that in LETO (Fig. 3b). Exenatide treatment tended to 
improve the survival rate in OLETF, but the difference did 
not reach statistical significance. In chloroquine-treated 
LETO, the survival rate (62%, Fig. 3c) tended to be lower 
than that in vehicle-treated LETO (Fig. 3a). Survival rates 
of chloroquine-treated OLETF were similar, regardless 
of vildagliptin treatment or no vildagliptin treatment (33 
and 39%, respectively, Fig. 3c), to the survival rate in vehi-
cle-treated OLETF (Fig. 3b). Autopsies of rats died within 
48 h after MI revealed no case of cardiac rupture.
Infarct sizes 48  h after the permanent coronary occlu-
sion were 35–40% of the left ventricle and were compa-
rable among the treatment groups (Fig.  3d–f). In LETO, 
hemodynamic parameters (heart rate and blood pressures) 
Fig. 2 Serum active GLP-1 level and oral glucose tolerance test in LETO and OLETF. a Serum level of the active form glucagon-like peptide 
(GLP-1) in OLETF treated with the vehicle or vildagliptin. Values in 4 of 5 samples from the vehicle-treated group were under the detection limit 
(<2.0 pmol/L) of the assay. Blood glucose (b) and serum insulin (c) during an oral glucose tolerance test (2 g glucose per kg body weight) in LETO 
(triangle) and OLETF treated with the vehicle (closed circle) or vildagliptin (open circle). *p < 0.05 vs. LETO and #p < 0.05 vs OLETF vehicle at each time 
point. N = 5 in each group. Vilda vildagliptin.
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at 12  h after MI in immunoblot experiments were com-
parable between the treatment groups (Table  3). Heart 
rates before and after MI and blood pressure at 12 h after 
MI were lower in OLETF than in LETO, but treatment 
with either vildagliptin or exenatide did not significantly 
change these hemodynamic parameters in OLETF. Taken 
together, these results indicate that difference in infarct 
size or hemodynamic response does not underlie the dif-
ference in survival rate among the treatment groups.
To examine whether the loading condition in the non-
infarcted region after MI was modulated by vildagliptin, 
we measured BNP mRNA level in the remote myocar-
dium 12 h after MI (Fig. 3g). BNP mRNA level was sig-
nificantly increased after MI in both LETO and OLEFT, 
but such an increase in BNP mRNA after MI was not 
observed in OLETF treated with vildagliptin (Fig.  3g). 
Since augmented adrenergic activity is one of the features 
of heart failure, we determined phosphorylation of vas-
odilator-stimulated phosphoprotein (VASP) at Ser157, 
a protein kianse A phosphorylation site, in the myocar-
dium. The levels of phospho-VASP after MI were simi-
lar in LETO and OLETF, but treatment of OLETF with 
vildagliptin significantly decreased phospho-VASP levels 
(Fig. 3h). These findings suggest that vildagliptin attenu-
ated both ventricular overloading and augmented adren-
ergic drive after MI in OLETF.
Autophagic response in the non‑infarcted region of the 
myocardium after MI was impaired in OLETF
Marker molecules of autophagic activities in the non-
infarcted region of the heart after MI are shown in Fig. 4. 
LC3-II levels in the heart without infarction (i.e., sham 
operation) were similar in LETO and OLETF. LC3-II/
vinculin ratio was significantly increased after MI in LETO, 
but such a response was not observed in OLETF (Fig. 4a). 
Changes in LC3-II/LC3-I ratio were similar to those in 
LC3-II/vinculin, though the difference did not reach statis-
tical significance. Vildagliptin significantly increased LC3-
II level and tended to increase LC3-II/LC3-I after MI in 
OLETF (Fig. 4b). Although p62 protein is often used as an 
index of autophagic flux [38], its level was not changed by 
MI in either LETO or OLETF (Fig. 4c). Neither vildagliptin 
nor exenatide changed p62 protein level after MI in OLETF 
(Fig. 4d). mRNA levels of p62 in the myocardium were also 
similar in LETO and OLETF regardless of MI and treat-
ment with vildagliptin or exenatide (data not shown).
Autophagic activity in the non-infarcted region of 
the myocardium was assessed also by immunostaining 
of autophagosomes with anti-LC3 antibody (Fig.  5). In 
LETO, the number of LC3-positive dots was significantly 
increased after MI by 66%, but such an increase was not 
observed in OLETF. Not only vildagliptin but also exena-
tide significantly increased the number of LC3 dot after 
MI in OLETF (Fig.  5), indicating that vildagliptin and 
exenatide restored autophagic induction in the non-
infarcted myocardium after MI in OLETF.
Activation of AMPK in response to MI was impaired 
in OLETF
Since AMPK is known to activate autophagy by phos-
phorylating ULK1 at Ser317 [25], we assessed AMPKα 
phosphorylation at Thr172 and phosphorylation of 
its downstream target proteins, acetyl-CoA carboxy-
lase (ACC) and ULK1, in the non-infarcted region after 
MI (Fig.  6a–c). Levels of phospho-Thr172-AMPKα, 
phospho-Ser79-ACC and phospho-Ser317-ULK1 were 
Table 2 Echocardiographic data at baseline
Values are mean ± SEM. N = 12–33.
HR heart rate, bpm beats per minute, LVEF left ventricular ejection fraction, FS fractional shortening, IVST interventricular septal thickness, PWT posterior wall thickness, 
LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-
systolic volume.
* P < 0.05 vs. LETO Vehicle.
LETO OLETF
Vehicle Vildagliptin Exenatide Chloroquine Vehicle Vildagliptin Exenatide Vildagliptin +  
Chloroquine
HR (bpm) 384 ± 6 386 ± 7 385 ± 4 375 ± 6 312 ± 7* 316 ± 4* 315 ± 6* 324 ± 9*
LVEF (%) 69.4 ± 1.5 70.8 ± 1.3 68.4 ± 1.2 73.0 ± 1.3 65.4 ± 1.5 67.7 ± 0.7 68.5 ± 1.3 69.9 ± 1.3
FS (%) 35.0 ± 1.3 35.9 ± 1.0 34.0 ± 0.8 37.6 ± 1.5 32.1 ± 1.1 33.4 ± 0.5 34.4 ± 1.0 35.2 ± 1.1
IVST (mm) 1.72 ± 0.04 1.69 ± 0.02 1.76 ± 0.03 1.75 ± 0.04 1.81 ± 0.04 1.74 ± 0.03 1.73 ± 0.03 1.85 ± 0.02
PWT (mm) 1.66 ± 0.06 1.73 ± 0.05 1.64 ± 0.02 1.76 ± 0.06 1.85 ± 0.05 1.79 ± 0.04 1.83 ± 0.06 1.84 ± 0.03
LVEDD (mm) 7.04 ± 0.12 6.71 ± 0.19 7.11 ± 0.12 6.68 ± 0.12 8.05 ± 0.18* 7.69 ± 0.10* 7.88 ± 0.12* 7.65 ± 0.15*
LVESD (mm) 4.60 ± 0.15 4.34 ± 0.13 4.69 ± 0.09 4.16 ± 0.14 5.49 ± 0.17* 5.08 ± 0.10* 5.17 ± 0.12* 4.94 ± 0.07*
LVEDV (ml) 0.80 ± 0.04 0.75 ± 0.04 0.83 ± 0.04 0.69 ± 0.03 1.17 ± 0.07* 1.02 ± 0.04* 1.10 ± 0.04* 1.00 ± 0.06*
LVESV (ml) 0.26 ± 0.02 0.22 ± 0.01 0.26 ± 0.02 0.19 ± 0.02 0.41 ± 0.03* 0.37 ± 0.04* 0.35 ± 0.02* 0.30 ± 0.01*
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Fig. 3 Effects of vildagliptin, exenatide, and chloroquine on survival after MI. Kaplan–Meier survival analysis of LETO (a), OLETF (b), and rats treated 
with chloroquine (c) after left coronary artery occlusion. *p < 0.05 vs. Vehicle-treated group. Infarct size measured at 48 h after MI in LETO (d), OLETF 
(e), and rats treated with chloroquine (f). g Quantification of BNP mRNA levels normalized to β-actin in the non-infarcted myocardium sampled 
12 h after MI. N = 3–6 in each group. h Summary data of immunoblotting for phospho-Ser157 VASP in samples from LETO, vehicle- or vildagliptin-
treated OLETF after MI. N = 9–12 in each group. Vilda vildagliptin, Exe exenatide, CQ chloroquine.
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significantly increased at 12 h after MI in LETO. In con-
trast, such responses of AMPKα, ACC and ULK1 were 
not detected in OLETF. Although vildagliptin and exena-
tide restored the increase in LC3-positive autophago-
somes after MI in OLETF (Fig. 5), neither agent restored 
phosphorylation of Thr172-AMPKα, Ser79-ACC or 
Ser317-ULK1 after MI in OLETF (Fig. 6d–f).
Akt/mTORC1 activity after MI was attenuated in the OLETF 
hearts
Alterations in Akt/mTORC1 signaling, a negative regu-
latory mechanism of autophagy [25], in OLETF were 
examined by immunoblotting. The level of Ser473-Akt 
phosphorylation was significantly elevated after MI in 
the non-infarcted myocardium in LETO (Fig.  7a). The 
Fig. 4 Vildagliptin restored autophagic induction in the non-infarcted area after MI in OLETF. a Representative images of Western blotting for LC3 
protein (left) and summary data of LC3-II level and LC3-II/LC3-I ratio (right) in samples from sham-operated hearts (Sham) or the non-infarcted 
myocardium after MI in LETO and OLETF. b Representative images of Western blotting for LC3 protein (left) and summary data of LC3-II level and 
LC3-II/LC3-I ratio (right) in samples from the non-infarcted myocardium after MI in OLETF treated with the vehicle, vildagliptin (Vilda), or exenatide 
(Exe). c Representative blots (left) and summary data (right) of Western blotting for p62 protein in samples from sham-operated hearts (Sham) or the 
non-infarcted myocardium after MI in LETO and OLETF. d Representative blots (left and middle) and summary data (right) of Western blotting for p62 
protein in OLETF treated with the vehicle, Vilda, or Exe after MI. N = 8–10 in each group. *p < 0.05. a.u. arbitrary units, NS not significant.
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Table 3 Hemodynamic data 12 h after myocardial infarction
Values are measn ± SE. N = 8–15.
SBP systolic blood pressure, DBP diastolic blood pressure, bpm beats per minute.
* P < 0.05 vs. LETO Sham.
LETO OLETF
Sham MI Sham MI
Vehicle Vehicle Vildagliptin Exenatide Vehicle Vehicle Vildagliptin Exenatide
SBP (mmHg) 119 ± 5 105 ± 6 115 ± 4 114 ± 5 104 ± 6 90 ± 3* 96 ± 4* 93 ± 5*
DBP (mmHg) 88 ± 4 81 ± 6 85 ± 4 82 ± 6 73 ± 7 64 ± 3* 65 ± 4* 64 ± 4*
Heart rate (bpm) 423 ± 7 401 ± 8 410 ± 11 400 ± 10 332 ± 13* 321 ± 6* 331 ± 7* 326 ± 9*
phosphorylation was associated with increases in lev-
els of phospho-mTOR at Ser2448 and phospho-S6 at 
Ser235/236 (Fig.  7b, c). However, such an activation of 
Akt after MI was not observed in OLETF; phospho-Akt 
levels were similar in sham-operated and MI-induced 
OLETF (Fig.  7a). Phospho-mTOR and phospho-S6 lev-
els were increased after MI in OLETF, but their levels 
remained significantly lower than those in LETO (Fig. 8b, 
c). Neither vildagliptin nor exenatide increased phospho-
rylation of Ser473-Akt, Ser2448-mTOR, and Ser235/236-
S6 after MI in OLETF (Fig. 7d–f).
Beclin‑1–Bcl‑2 interaction was enhanced in OLETF
Since vildagliptin improved the response of autophagic 
activity to MI in OLETF (Figs. 4, 5) without normaliza-
tion of AMPK phosphorylation and Akt/mTORC1 sign-
aling (Figs.  6, 7), we examined whether Beclin-1–Bcl-2 
interaction is modified in OLETF or by vildagliptin treat-
ment. Beclin-1 is an essential component for activation 
of autophagy, and its autophagy-promoting activity is 
inhibited by binding to an anti-apoptotic protein, Bcl-2 
[39]. There were no significant differences in Beclin-1 and 
Bcl-2 protein levels between LETO and OLETF regard-
less of MI (Fig. 8a), and neither vildagliptin nor exenatide 
changed levels of these proteins in MI-induced OLETF 
(Fig. 8b). However, Beclin-1–Bcl-2 interaction was signif-
icantly augmented in OLETF with MI compared to that 
in OLETF with a sham operation, and their interaction 
was attenuated by vildagliptin (Fig. 8c–e).
Discussion
In the present study, treatment with vildagliptin at a 
dose that did not lower plasma glucose level significantly 
improved survival of OLETF after acute MI (Figs.  2, 3). 
By using telemetric monitoring of heart rate and blood 
pressure, we previously demonstrated that increased 
mortality during the acute phase after MI in OLETF is 
due to progressive heart failure but not lethal arrhyth-
mia [4]. Although vildagliptin did not modify ventricular 
Fig. 5 Immunofluorescent analysis of LC3 protein in the non-
infarcted myocardium after MI. a Representative immunofluores-
cence images of LC3 protein in LV sections from the non-infarcted 
myocardial area after MI. The image without the primary antibody 
did not show any green dots. b Quantification of LC3 dots per field 
(568 µm × 426 µm). A total of 40 fields from five hearts were analyzed 
in each group. *p < 0.05. Vilda vildagliptin, Exe exenatide, NS not 
significant.
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Fig. 6 Analysis of the AMPK/ULK1 pathway. Representative images (left) and summary data (right) of Western blotting for phospho-Thr172 and total 
AMPKα (a), phospho-Ser79 and total acetyl-CoA carboxylase (ACC) (b), and phospho-Ser317-ULK1 (c) in samples from sham-operated heats or the 
non-infarcted myocardium after MI in LETO and OLETF. Representative blots (left) and summary data (right) of Western blotting for phospho-Thr172 
and total AMPKα (d), phospho-Ser79 and total acetyl-CoA carboxylase (ACC) (e), and phospho-Ser317-ULK1 (f) in the non-infarcted myocardium 
after MI in OLETF treated with the vehicle, vildagliptin (Vilda), or exenatide (Exe). N = 9–10 in each group. *p < 0.05. a.u. arbitrary units, NS not signifi-
cant.
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Fig. 7 Analysis of Akt/mTORC1 activity. Representative blots (left) and summary data (right) of Western blotting for phospho-Ser473 and total Akt 
(a), phospho-Ser2448 and total mTOR (b), and phospho-Ser235/236 and total S6 (c) in samples from sham-operated heats or the non-infarcted 
myocardium after MI in LETO and OLETF. Representative blots (left) and summary data (right) of Western blotting for phospho-Ser473 and total Akt 
(d), phospho-Ser2448 and total mTOR (e), and phospho-Ser235/236 and total S6 (f) in the non-infarcted myocardium after MI in OLETF treated with 
the vehicle, vildagliptin (Vilda), or exenatide (Exe). N = 9–10 in each group. *p < 0.05. a.u. arbitrary units.
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function under baseline conditions (Table  2), it sup-
pressed MI-induced upregulation of BNP expression and 
cardiac adrenergic activity in OLETF (Fig.  3g, h). Thus, 
suppression of heart failure progression after MI is the 
most likely explanation for reduction in acute mortality 
after MI in OLETF by vildagliptin.
Serum active GLP-1 level was elevated by vildagliptin 
(Fig.  2a), suggesting that GLP-1 mediated the improved 
survival by vildagliptin. On the other hand, treatment 
with a GLP-1 analog, exenatide, tended to improve 
post-MI survival in OLETF, but the effect was statisti-
cally insignificant. We do not have a clear explanation 
for the different outcomes in the vildaglitpin-treated 
and exenatide-treated groups. However, a difference in 
the mechanism of cardioprotection is a possibility. The 
GLP-1 receptor is localized in the cardiomyocyte [40], 
but a   recent study has shown that a GLP-1 receptor 
agonist provides cardioprotection by a mechanism inde-
pendent of the GLP-1 receptor in the cardiomyocyte [31]. 
On the other hand, DPP-4 is involved in degradation of 
multiple peptides such as substance P and stromal cell-
derived factor-1 [27, 41], and these properties of DPP-4 
inhibitors might underlie the differences in survival rate 
(Fig.  3b) and changes in LC3-II protein level (Fig.  4b) 
after MI between vildagliptin-treated and exenatide-
treated OLETF.
In the literature, a study by French et  al. [42] is the 
only study in which the changes in autophagy after MI 
in diabetic mice and non-diabetic mice were compared. 
In that study, autophagic activity was not increased after 
MI not only in the diabetic heart but also in the non-dia-
betic heart. The negative results are in contrast to results 
Fig. 8 Effect of vildagliptin on Beclin-1/Bcl-2 interaction after MI in OLETF. a Representative images (left) and summary data (right) of Western 
blotting for Beclin-1 and Bcl-2 in samples from sham-operated heats or the non-infarcted myocardium after MI in LETO and OLETF. b Effects of 
vildagliptin (Vilda) and exenatide (Exe) on Beclin-1 and Bcl-2 levels in the non-infarcted myocardium after MI in OLETF. Representative immunoblot-
ting images (left) and summary data (right) are shown. c Myocardial lysates were immunoprecipitated (IP) with anti-Beclin-1 antibody or rabbit IgG 
followed by immunoblotting with anti-Bcl-2 and Beclin-1 antibodies. d, e Beclin-1/Bcl-2 interaction was increased after MI in OLETF, which was 
attenuated by vildagliptin (Vilda). N = 5 in each group. *p < 0.05. a.u. arbitrary units.
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of several studies showing that autophagic activity was 
increased after MI in the healthy control myocardium [5, 
8–12]. The reason why French et al. could not detect an 
alteration of autophagy after MI even in the non-diabetic 
myocardium is unclear, but use of entire risk zone tissue 
consisting of infarcted and non-infarcted cells might have 
obscured changes in autophagy in the viable myocardium 
after MI.
We focused on the non-ischemic region of the 
infarcted heart since that region plays a crucial role 
in compensation for the lost function of the infarcted 
region and undergoes adaptive and maladaptive post-MI 
remodeling [43, 44]. There was no significant difference 
in LC3-II or p62 levels or LC3-positive autophagosomes 
between LETO and OLETF under baseline conditions 
(i.e., sham-operated groups in Figs. 4, 5), suggesting that 
autophagic activities were similar in the diabetic myocar-
dium and non-diabetic myocardium under non-stressed 
conditions. However, there was a significant difference 
between LETO and OLETF in autophagic response 
after MI. In LETO, an increase in autophagic activity 
was observed in the non-infarct region at 12 h after MI 
(Figs. 4, 5). A protective role of the increase in autophagic 
activity after MI has been demonstrated by findings that 
inhibition of autophagy by bafilomycin A or genetic dele-
tion of beclin-1 aggravated remodeling and dysfunction 
of the ventricle after MI [8, 11]. Importantly, the mor-
tality rate after MI in OLETF was not further increased 
by inhibiting autophagy with chloroquine (Fig. 3). These 
results support the notion that impaired autophagic 
response in the non-infarcted region of the infarcted 
heart contributes to increase in acute mortality after MI 
in OLETF.
There are two possible mechanisms for suppression 
of heart failure by autophagy: reduction of reactive 
oxygen species (ROS) production and improvement of 
myocardial energy status. Damaged organelles partici-
pating in ROS generation, including mitochondria, are 
sequestrated and removed by the autophagic process, 
and autophagy plays a role in suppression of ROS gen-
eration [17, 45]. In fact, ROS generation from damaged 
mitochondria is involved in exacerbation of ventricu-
lar dysfunction [46]. An impact of autophagy on myo-
cardial energy status has been shown by findings that 
myocardial ATP content after MI was increased by aug-
mentation of autophagy [9]. Diabetes impairs mecha-
nisms regulating ATP supply, and our recent study [33] 
showed that reduced myocardial reserve of ATP sup-
ply, leading to diastolic dysfunction, was disclosed by 
increased afterload in OLETF. How impaired response 
of autophagy relates to dysregulation of ATP supply 
mechanisms in diabetic hearts may warrant further 
investigation.
The results of the present study supported the notion 
that activation of autophagy by vildagliptin during the 
acute phase after MI contributed to improved survival 
in OLETF. However, roles of autophagy in the heart may 
be different depending on the phase and type of cardiac 
stress. Matsui et  al. [5] showed that autophagy is pro-
tective for cardiomyocyte survival during ischemia but 
is rather detrimental during reperfusion. Zhu et  al. [47] 
showed that sustained activation of autophagy during 
pressure overload is detrimental to cell survival. They 
showed that cardiac function after thoracic aortic band-
ing was preserved in beclin-1 heterozygous knockout 
mice, whereas cardiomyocyte-specific overexpression 
of beclin-1 worsened cardiac function. In contrast, sus-
tained elevation of autophagy may be protective for 
post-infarcted ventricular function and remodeling. Sup-
pression of autophagy by bafilomycin A1 or chloroquine 
has been shown to exacerbate cardiac function after MI, 
but activation of autophagy by an mTORC1 inhibitor, 
rapamycin, or by caloric restriction was protective [8, 12]. 
Maejima et  al. [11] also reported that cardiac function 
at 6 weeks after MI was worsened in beclin-1 heterozy-
gous knockout mice. Since the survival rate of OLETF at 
48 h after MI was only 32% (Fig. 3b), we did not include 
assessment of autophagic activity at the later phase after 
MI in OLETF in the present study.
Streptozotocin-induced diabetes and high-fat diet 
have been shown to reduce LC3-II in the myocardium, 
which was associated with suppressed phosphorylation 
of AMPK, a positive regulator of autophagy [16, 18]. In 
contrast, LC3-II, p62 or AMPK phosphorylation in the 
heart without MI was not different between OLETF and 
LETO in this study. However, Lee et  al. [48] reported 
50% reduction in AMPK phosphorylation in the myo-
cardium of OLETF at the age of 28  weeks. A possible 
explanation for the discrepant results is more advanced 
stage of T2DM in OLETF in the study by Lee et al. [48]. 
Despite similar ages, OLETF in their study had slightly 
larger body weight compared with that in this study and 
showed significantly increased interstitial fibrosis in the 
heart [48], though such an increased collagen deposition 
in the myocardium was not detected by histochemistry 
or determination of mRNA levels of collagens I and III 
in OLETF used in our studies [4, 33]. Some difference in 
rearing conditions (possibly the amount or calories per 
volume of the chow provided) might underlie the differ-
ence in the phenotype of OLETF at similar ages. Never-
theless, it is possible that suppression of baseline AMPK 
phosphorylation and autophagy occurs in OLETF at an 
advanced stage of T2DM.
Increased AMPK phosphorylation with or without 
suppressed mTOR phosphorylation was associated with 
promotion of autophagy after MI in non-diabetic mice 
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[9, 16]. The responses of autophagy, AMPK and mTOR 
to MI were confirmed in LETO (Figs. 4, 5, 6, 7). However, 
in OLETF, phosphorylation of AMPK was not increased 
and activation of the mTOR/S6 pathway was 60–70% of 
that in LETO (Figs. 6, 7). In addition, we found that inter-
action of Beclin-1 and Bcl-2, which reportedly inhibits 
Beclin-1-dependent autophagy [11, 15, 39], was signifi-
cantly increased in the myocardium of OLETF (Fig.  8). 
Restoration of the adaptive responses of both LC3-II and 
autophagosomes after MI in OLETF by vildagliptin was 
associated with suppression of Beclin-1–Bcl-2 interac-
tion but not with improved phosphorylation of AMPK, 
mTOR or S6. These findings suggest that increased 
Beclin-1–Bcl-2 interaction was responsible for T2DM-
induced loss of adaptive autophagy in the non-ischemic 
myocardium after MI.
How vildagliptin suppressed Becin-1–Bcl-2 interac-
tion in the myocardium of OLETF remains unclear. 
Among molecules that regulate Beclin-1–Bcl-2 interac-
tion, AMPK-JNK activation has been reported to induce 
disruption of Beclin-1–Bcl-2 interaction through phos-
phorylation of Bcl-2 at Ser70 [15], whereas activation 
of mammalian sterile 20-like kinase 1 (Mst1) promoted 
Beclin-1/Bcl-2 interaction by phosphorylation of Bec-
lin-1 at Thr108 [11]. In this study, vildagliptin did not 
restore phosphorylation of AMPK (Fig.  6) or JNK (data 
not shown). Hence, there is the possibility that vildaglip-
tin suppressed Mst1 expression or activity, preventing 
interaction of Beclin-1 and Bcl-2 in the myocardium of 
OLETF. Unfortunately, we could not examine this pos-
sibility since phospho-Mst1 (Thr183) protein in the 
myocardium of OLETF could not be detected by use of 
commercially available antibodies.
Contrary to our expectations, the dose of vildagliptin 
we used in the present study was not sufficient for reduc-
ing glucose levels in OLETF (Table 1; Fig. 2b), though the 
dose of vildagliptin increased serum active GLP-1 level 
in OLETF (Fig. 2a). Therefore, the effects of vildagliptin 
on cardiac autophagy and mortality cannot be explained 
by its effect on glycemic control. Although DPP-4 inhibi-
tors are known to enhance glucose-stimulated insulin 
release [49], reduction in plasma insulin level by DPP-4 
inhibitors together with improved metabolic parameters 
has also been reported [50, 51]. It is notable that DPP-4 
inhibitors (saxagliptin and alogliptin) failed to reduce 
cardiovascular mortality in diabetic patients at high car-
diovascular risk in two large clinical trials [52, 53]. The 
effect of vildagliptin on acute mortality after MI in this 
study (Fig. 3) is difficult to easily reconcile with the nega-
tive results in the clinical trials [52, 53]. However, there 
is the possibility that the optimal dose of DPP-4 for 
cardiprotection is lower than that for glycemic control.
Conclusions
Treatment with vildagliptin at a dose that elevated serum 
GLP-1 without normalization of plasma glucose level 
reduced acute mortality after MI in a rat model of T2DM 
to the level in non-diabetic controls. The beneficial effect 
of vildagliptin was sensitive to chloroquine and closely 
associated with restoration of the autophagic response 
in the non-infarcted myocardium to MI, suggesting an 
involvement of impaired autophagy in T2DM-induced 
increase in post-MI mortality.
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